Goldman Sachs Downgrades 2Seventy Bio Stock Amid Market Challenges
Thursday, 6 June 2024, 06:33
Goldman Sachs Downgrades 2Seventy Bio Stock
Goldman Sachs recently downgraded 2Seventy Bio stock due to market challenges. The stock's performance is under pressure as the company faces uncertain market conditions. This downgrade by Goldman Sachs has significant implications for investors.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.